Perseus Proteomics Inc Relative Valuation - Perseus Proteomics Inc - Alpha Spread

Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 588 JPY 1.03% Market Closed
Market Cap: 8.7B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Relative Value

The Relative Value of one Perseus Proteomics Inc stock under the Base Case scenario is 650.97 JPY. Compared to the current market price of 588 JPY, Perseus Proteomics Inc is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
650.97 JPY
Undervaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
17
Median 3Y
56.1
Median 5Y
56.1
Industry
7.7
Forward
4.1
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-6.6
Industry
23.9
Forward
9
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-9.4
Industry
22.2
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-8.1
Industry
24
vs History
12
vs Industry
15
Median 3Y
1.7
Median 5Y
1.7
Industry
2.5
vs History
9
vs Industry
16
Median 3Y
22.3
Median 5Y
22.3
Industry
7.4
Forward
3.1
vs History
7
vs Industry
11
Median 3Y
23.5
Median 5Y
23.5
Industry
8.5
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.9
Industry
5.1
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.9
Industry
4.7
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-4.1
Industry
6.6
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-3.6
Industry
4.7
vs History
14
vs Industry
7
Median 3Y
23.9
Median 5Y
23.9
Industry
4.7

Multiples Across Competitors

Competitors Multiples
Perseus Proteomics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Perseus Proteomics Inc
TSE:4882
8.4B JPY 86.7 -9.3 -7.1 -7.1
US
Abbvie Inc
NYSE:ABBV
341.5B USD 6.2 64.5 15.7 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
105B USD 3.8 99.7 9.5 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 975 -504 -548.8 -534.2
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.4 22.3 27.8
US
Seagen Inc
F:SGT
39.3B EUR 19 -58.3 -62.8 -56.7
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.2B USD 15 -483 212.6 327.3
P/E Multiple
Earnings Growth
JP
Perseus Proteomics Inc
TSE:4882
Average P/E: 57.6
Negative Multiple: -9.3
N/A
US
Abbvie Inc
NYSE:ABBV
64.5
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.7
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
AU
CSL Ltd
ASX:CSL
36.4
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -483 N/A
EV/EBITDA Multiple
EBITDA Growth
JP
Perseus Proteomics Inc
TSE:4882
Average EV/EBITDA: 47.6
Negative Multiple: -7.1
N/A
US
Abbvie Inc
NYSE:ABBV
15.7
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.5
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.8 N/A
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
212.6
N/A
EV/EBIT Multiple
EBIT Growth
JP
Perseus Proteomics Inc
TSE:4882
Average EV/EBIT: 69.3
Negative Multiple: -7.1
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A
AU
CSL Ltd
ASX:CSL
27.8
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
327.3
N/A

See Also

Discover More
Back to Top